HPGDS and cancer: Multiple mechanisms of ADR resistance in cancers have been proposed in the last decades, including decreased drug accumulation, upregulating expression of drug efflux transporters such as multidrug resistance protein and P‐ glycoprotein, increased DNA repair activity, or excessive detoxification by Glutathione S‐transferases (GSTs)/ Glutathione (GSH) systems.2, 3, 4